Clinical trial Recruiting at 1 site Interventional Ages 18 to 75 Women only

Evaluating endoscopic-assisted mastectomy with immediate breast reconstruction for breast cancer

Official title: A Prospective, Single-center, Double-arm Clinical Study to Evaluate the Effectiveness and Safety of Mastectomy Combined With Immediate Breast Reconstruction in Breast Cancer (NJMU-Reconstruction Cohort)

Run by The First Affiliated Hospital with Nanjing Medical University · NCT06817954 · Data updated 2026-11-12

This study is testing a new way to perform mastectomy with immediate breast reconstruction using advanced technology to see if it helps breast cancer patients recover better than traditional methods.

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexWomen only
Enrollment800 (estimated)
SponsorThe First Affiliated Hospital with Nanjing Medical University
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Nanjing, Jiangsu)
StatusRecruiting
StartedJanuary 1, 2025
Main results expectedDecember 31, 2027
Study endsDecember 31, 2028
Registry record updatedMay 1, 2026
Trial IDNCT06817954 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are female patients aged 18-75 with diagnosed breast cancer suitable for unilateral mastectomy and immediate reconstruction.

Probably not a fit

Patients with advanced breast cancer showing signs of invasion to the skin, chest wall, or nipple areola complex may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the effectiveness and safety of a new endoscopic-assisted technique for mastectomy combined with immediate breast reconstruction in patients with breast cancer. The study is a prospective, single-center, double-arm trial that will compare the outcomes of this innovative approach against traditional methods. By utilizing advanced technology, the trial seeks to improve surgical outcomes and patient recovery times. The research is particularly focused on patients with specific tumor characteristics and stages, ensuring a targeted approach to treatment.

Why it matters

Potential benefit: If successful, this approach could lead to improved surgical outcomes and enhanced recovery for breast cancer patients undergoing mastectomy and reconstruction.

How similar studies have gone: While the endoscopic-assisted approach is relatively novel in this context, similar studies have shown promising results in other surgical fields, indicating potential for success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Female patients, aged 18-75 years old; The pregnancy test (-) and reliable contraceptive methods are required for premenopausal and perimenopausal patients;
2. Patients with the diagnosed breast cancer confirmed by core needle biopsy and unilateral operation was performed; Breast cancer patients with tumor node metastasis stage 0-III according to the 8th edition of the American Joint Commission on Cancer; Preoperative clinical examination or imaging evaluation shows that the distance between the tumor and the Nipple Areolar Complex (NAC) is more than 1cm. The tumor has a diameter of 2-3 cm and can be located in any quadrant or reduced to 3 cm through preoperative neoadjuvant chemotherapy. The distance between the lesion and the skin should be at least 8-10 mm;
3. There is no clinical or imaging evidence to prove that the tumor has invaded the skin, chest wall, or nipple areola complex;
4. There are indications for breast preservation, but the patient has a strong desire for reconstruction and is unwilling to undergo breast preservation surgery;
5. Preventive mastectomy (BRCA1/2 malignant mutation with obvious family history of breast cancer and other high-risk groups);
6. Preoperative clinical manifestations and imaging data showed no distant metastasis;
7. No history of breast cancer or other serious underlying diseases in the past;
8. Karnofsky performance status score ≥ 70;
9. Eastern Cooperative Oncology Group score ≤ 2 ;
10. The surgical procedure includes endoscopic-assisted/conventional mastectomy, sentinel lymph node biopsy/axillary lymph node dissection and immediate breast reconstruction;
11. Participants are able to understand the research process, voluntarily join the study, sign informed consent forms, have good compliance, and cooperate with follow-up;
12. No swallowing difficulties; No shoulder joint movement disorders;
13. Complete clinical data.

Exclusion Criteria:

1. Male breast cancer or inflammatory breast cancer;
2. Metastatic breast cancer (stage IV); Tumor invasion of the skin, pectoralis major muscle, or NAC;
3. The clinical data is basically incomplete;
4. Previously received chemotherapy in an external hospital or has undergone tumor resection in an external hospital;
5. Bilateral breast cancer surgery;
6. Other surgical methods;
7. Preoperative distant metastasis or supraclavicular lymph node dissection;
8. Complicated with other malignant tumors or had malignant tumors other than breast cancer in recent 5 years;
9. The serious disease of non malignant tumors combined will affect the patient's compliance or put the patient in a dangerous state;
10. Dementia, intellectual disability, or any mental illness that hinders understanding of informed consent forms.

Where it's running

  • The First Affiliated Hospital with Nanjing Medical University
    Nanjing, Jiangsu, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.